Cit­ing a ‘con­flict,’ GSK vet Slaoui abrupt­ly quits In­tel­lia board

Not long af­ter re­tir­ing from Glax­o­SmithK­line, where he led R&D and then the vac­cines group, Mon­cef Slaoui start­ed sign­ing up for a va­ri­ety of biotech boards. There was a seat at the ta­ble for SutroVax, mR­NA play­er Mod­er­na as well as the pub­lic out­fit In­tel­lia $NT­LA, one of a hand­ful of CRISPR/Ca9 gene edit­ing star­tups dom­i­nat­ing the field.

Then, ear­li­er to­day, he was sud­den­ly gone.

In an SEC fil­ing In­tel­lia not­ed that Slaoui had abrupt­ly de­part­ed on Mon­day “due to a con­flict of in­ter­est.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER